Nous utilisons des cookies et des outils d'analyse (Google Analytics, Google Tag Manager) pour améliorer votre expérience. En acceptant, vous consentez à l'utilisation de ces technologies. Vous pouvez modifier vos préférences à tout moment.

blog.fallback_notice_title
blog.fallback_notice_body
blog.key_takeaways
The botulinum toxin market is no longer limited to a single dominant brand. Alongside Allergan Botox and Merz Xeomin, Korean products such as Letybo and Nabota are now part of real-world treatment planning in many clinics.
For patients, the important question is not whether a product is Korean or American, but whether it is original, properly stored, legally sourced, and matched to the right treatment plan. Brand choice matters, but injector judgement matters more.
Letybo by Hugel and Nabota by Daewoong are botulinum toxin type A products developed in South Korea. They are widely discussed because they promise a balance of clinical performance and lower cost compared with older premium brands.
In practice, both products are evaluated through the same lens as any other toxin: onset speed, diffusion profile, consistency of response, immunogenicity concerns, and reliability of the distribution chain.
Allergan Botox remains the reference brand for many injectors because of its long track record and highly familiar dose behavior. Xeomin is often highlighted for its purified formula without complexing proteins, which can be relevant in long-term planning for selected patients.
Korean toxins can be very reasonable options when the product is authentic and the clinician understands its practical behavior. The brand should be selected according to treatment goals, expected onset, patient history, and confidence in the supply chain.
Dr. Gemici: A toxin brand is not good simply because it is famous or inexpensive. I care about predictability, authentic sourcing, proper storage, and whether the product matches the patient in front of me.
Patients often focus on the name of the vial, but the safer questions are more practical: Is the product original? Is it supplied through an authorized route? How is it stored? Which brand does the injector personally use most confidently?
A lower price is not automatically a better decision if the product origin is unclear or the injector is unfamiliar with its clinical behavior. In toxin treatments, trust in the clinician and clinic standards is more valuable than chasing the cheapest vial.
Patients who want the most established benchmark often feel more comfortable with Allergan Botox. Patients with specific long-term planning concerns may discuss Xeomin. Those seeking a more cost-conscious option may consider Korean brands, provided the clinic uses authentic products and has experience with them.
The best choice is individualized. The goal is not to defend one brand ideologically, but to select the product that offers the most reliable and natural outcome for the planned treatment area.
They can be safe when the product is original, legally sourced, properly stored, and used by an experienced injector. The source chain matters as much as the brand name.
Not universally. Some clinicians like its practical behavior and pricing, but Allergan remains the benchmark for many. The right choice depends on the clinic and the treatment plan.
Xeomin is often chosen for its purified profile and predictable use in selected long-term treatment plans.

Trusted & Professional
Dr Hamza Gemici est un médecin en esthétique médicale basé à Ataşehir, Istanbul. Sa pratique repose sur un anti-âge naturel et une harmonisation subtile du visage à l aide de toxine botulique, fillers dermiques, rajeunissement péri-oculaire et traitements de qualité cutanée. Toutes les procédures sont réalisées avec des produits approuvés FDA et sous protocole médical.